Treatment of chronic hepatitis B in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 1 SUPPL. 1, 2006, Pages

  Jonas, Maureen M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Hepatitis B; Interferon alpha; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ANOREXIA; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; CHILD; CHILDHOOD DISEASE; CHRONIC HEPATITIS; DISEASE ASSOCIATION; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HUMAN; INFANT DISEASE; LIVER CIRRHOSIS; MOOD DISORDER; MORBIDITY; MYALGIA; NEUTROPENIA; PATIENT SELECTION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; HEPATITIS B, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; LAMIVUDINE;

EID: 33745736799     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000226391.02355.1b     Document Type: Article

References (44)

1. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infec Dis 2002;185:713-9.
2. Lok ASF, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-3.
3. Hsu H, Chang M, Chen D, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986;18:301-7.
4. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990;99:805-10.
5. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-90.
6. Kleinknecht C, Levy M, Peix A, et al. Membranous glomerulonephritis and hepatitis B surgace antigen in children. J Pediatr 1979;95:946-52.
7. Southwest Pediatric Nephrology Study Group. Hepatitis B surface antigenemia in North American children with membranous glomerulonephropathy. J Pediatr 1985;106:571-8.
8. Ozdamar SO, Gucer S, Tinaztepe K. Hepatitis-B virus associated nephropathies: a clinicopathological study in 14 children. Pediatr Nephrol 2003;18:23-8.
9. Tanaka T, Miyamoto H, Hino O, et al. Primary hepatocellular carcinoma with hepatitis B virus-DNA-integration in a 4-year-old boy. Hum Pathol 1986;17:202.
10. Cheah PL, Looi LM, Lin HP, et al. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer 1990;65:174-6.
11. Giacchino R, Navone C, Facco F, et al. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991;36:1143-6.
12. Pontisso P, Basso G, Perilongo G, et al. Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Canc Detect Prevent 1991;15:363-8.
13. Hsu HC, Wu MZ, Chang MH, et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5:260-7.
14. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1906-7.
15. Godra A, Jonas MM, Perez-Atayde AR. Histopathology of the liver in children with chronic hepatitis B (abstract). Modern Pathology 2005;18:346.
16. American Academy of Pediatrics. School health. In: LK P, ed. 2001 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2000:124-7.
17. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
18. Kobak GE, MacKenzie T, Sokol RJ, et al. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr 2004;145:340-345. Available at: http:// www2.us.elsevierhealth.com/scripts/om. dll/serve?article= as0022347604004597.
19. Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15:143-8.
20. Gurakan F, Kocak N, Ozen H, et al. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-6.
21. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-90.
22. Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alfa therapy on growth of children. J Viral Hepat 2001;8:139-47.
23. Jonas MM, Kelly DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
24. Sokal E, Mizerski J, Woynarowski M, et al. An extended, stratified, follow-on study in children with chronic hepatitis B (CHB) who have completed previous lamivudine studies [abstract]. Hepatology 2003;38(Suppl 1):710.
25. Liaw Y-F, Leung NWY, Chang T-T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;2000:172-80.
26. Leung NWY, Lai C-L, Chang T-T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
27. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-92.
28. Selimoglu MA, Aydogdu S, Unal F, et al. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int 2002;44:404-8.
29. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
30. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
31. Marcellin P, Chang TT, Lim S, et al. Long term efficacy and safety of adefovir dipivoxil 10mg in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time [abstract]. Hepatology 2004;40(Suppl 1):655A.
32. Janssen HLA, van Zonneveld M, Senturk H, et al. Pegylated Interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9.
33. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med 2004;351:1206-1217. Available at: http://content.nejm.org/ cgi/content/abstract/351/12/1206.
34. Naoumov NV, Hou J. The emerging role of hepatitis B virus genotypes. Curr Hepatitis Rep 2004;3:145-51.
35. Ni YH, Chang MH, Wang JK, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004;127:1733-8.
36. Wai CT, Chu C-J, Hussainn M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
37. Kao J-H, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon. J Hepatol 2000;33:998-1002.
38. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterology 2003;9:2695-7.
39. Moskovitz DN, Osiowy C, Giles E, et al. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic B. hepatitis, role of genotype and drug resistance. J Viral Hepat 2005;12:398-404.
40. Westland C, Delaney W IV, Yang H. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003;125:107-16.
41. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13. Available at: http://gut.bmjjournals.eom/ cgi/content/abstract/54/7/ 1009.
42. Broderick A, Jonas MM. Management of hepatitis B in children. Clin Liver Dis 2004;8:387-401.
43. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-7.
44. Hom X, Little NR, Gardner SD, et al. Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B. Pediatr Infect Dis J 2004;23:441-5.